drugset

drugset / Trial / NCT02074995

Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

NCT02074995 ↗

Phase 2 Terminated 1 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupTriple-blindTreatment

Summary

Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks

Timeline

Start: 2014-02
Primary completion: 2015-01
Completion: 2015-01

Outcome

Outcome not reported

Stopped (Enrollment): “The study was prematurely terminated due to recruitment issues”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BVS857	Unknown	0.03 mg/kg	Intravenous

Indications